The efficacy of molnupiravir in patients with COVID-19

Phase 2

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20210914052480N2
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Living in a family with at least one infected person with COVID-19
Not having pulmonary involvement
Not having symptoms like chest wall pain and dysnea suggesting pulmonary involvement
Positive PCR test of COVID-19
Patient with COVID-19 symptoms lesser than 3 days
Patients satisfied with consumption of oral medication
Blood oxygen saturation above 93 percents

Exclusion Criteria

Patients under 18 years old
Having underlying diseases such as uncontrolled diabetes, uncontrolled blood pressure, liver and heart disease and kidney, heart and liver failure
History of any of the diseases including hepatitis B or C, HIV, autoimmune diseases and immunodeficiency
History of hepatocellular disease, liver failure and heart failure of liver tests more than 3 times normal
History of allergy to antiviral drugs
Existence of thrombocytopenia (platelets under 100000)
History of recent COVID-19 vaccination lesser than 7 days
being pregnant
breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified